x min read

Momentum Stocks: Theravance Biopharma, Inc. (NASDAQ:TBPH), 22nd Century Group, Inc. (NYSEMKT:XXII), Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), Midstates Petroleum Company (NYSE:MPO), Symantec Corporation (NASDAQ:SYMC)

Momentum Stocks: Theravance Biopharma, Inc. (NASDAQ:TBPH), 22nd Century Group, Inc. (NYSEMKT:XXII), Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), Midstates Petroleum Company (NYSE:MPO), Symantec Corporation (NASDAQ:SYMC)
Written by
Charles Donlon
Published on
November 14, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), through its U.S. operating subsidiary, Theravance Biopharma US, Inc., on 06 November 2014 reported financial results for the third quarter 2014. Revenue for the third quarter of 2014 was $6.3 million. Net loss for the third quarter of 2014 was $54.5 million or $1.72 per share. Cash, cash equivalents, and marketable securities totaled $350.4 million as of September 30, 2014. Theravance Biopharma, Inc. (NASDAQ:TBPH) belongs to Healthcare sector. Its weekly performance is 0.97%. On last trading day company shares ended up $17.61. Theravance Biopharma, Inc. (NASDAQ:TBPH) distance from 50-day simple moving average (SMA50) is -21.30%. Joseph Pandolfino has been terminated as CEO at 22nd Century Group Inc. (NYSEMKT:XXII) but will remain on the board and may begin a new role as chief technology officer. According to documents filed Monday with the SEC, the Clarence company's board on Saturday terminated Pandolfino's employment agreement, dated Jan. 25, 2011, without cause and agreed to severance payments. 22nd Century Group, Inc. (NYSEMKT:XXII) shares decreased -3.56% in last trading session and ended the day at $2.17. XXII Gross Margin is 90.90% and its return on assets is -311.20%. 22nd Century Group, Inc. (NYSEMKT:XXII) quarterly performance is -23.86%. Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced at The Liver Meeting®2014 results from studies in chronic hepatitis C virus (HCV) patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I). On 13 November, Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares decreased -0.21% and was closed at $43.22. ENTA EPS growth in last 5 year was 0.00%. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) year to date (YTD) performance is 58.43%. Midstates Petroleum Company (NYSE:MPO) last released its earnings data on Tuesday, November 4th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.19. The company had revenue of $224.80 million for the quarter, compared to the consensus estimate of $171.90 million. The company’s revenue for the quarter was up 101.6% on a year-over-year basis. Analysts expect that Midstates Petroleum Company will post $0.57 EPS for the current fiscal year. Midstates Petroleum Company, Inc. (NYSE:MPO) ended the last trading day at $2.94. Company weekly volatility is calculated as 12.29% and price to cash ratio as 8.06. Midstates Petroleum Company, Inc. (NYSE:MPO) showed a weekly performance of -3.29%. Symantec Corp. (NASDAQ:SYMC) in alliance with Deloitte announced an innovative cyber threat vulnerability management service. The integrated offering will pair Symantec’s cyber intelligence and information protection technologies with Deloitte’s consulting services to help businesses address concerns around cyber security and information protection. The alliance will focus on growth markets across EMEA, including Middle East as a priority region given it is a hub of targeted cyber crime activity. Symantec Corporation (NASDAQ:SYMC) shares moved up 1.71% in last trading session and ended the day at $25.55. SYMC Gross Margin is 82.70% and its return on assets is 7.40%. Symantec Corporation (NASDAQ:SYMC) quarterly performance is 6.06%.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.

Recommended for You